Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 févr. 2018 07h00 HE | Source: ObsEva SA

ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
01 févr. 2018 07h00 HE | Source: ObsEva SA

Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
05 janv. 2018 07h00 HE | Source: ObsEva SA

ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
07 déc. 2017 07h00 HE | Source: ObsEva SA

ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA...
05 déc. 2017 07h00 HE | Source: ObsEva SA

ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} OBE022 is a first-in-class, oral and...
14 nov. 2017 07h00 HE | Source: ObsEva SA

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - All Three Development Compounds...
07 nov. 2017 07h00 HE | Source: ObsEva SA

ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
31 oct. 2017 07h00 HE | Source: ObsEva SA

ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
10 oct. 2017 08h00 HE | Source: ObsEva SA

ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA - 10...
11 sept. 2017 07h00 HE | Source: ObsEva SA

ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Phase 1 clinical trial results in...

Page précédente